Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Latest Information Update: 28 Sep 2024
At a glance
- Drugs Anetumab ravtansine (Primary) ; Pembrolizumab
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2024 Results evaluating anetumab ravtansine in combination with the programmed cell death-1 (PD-1) inhibitor pembrolizumab based on the common expression of mesothelin and reports of activity in mesothelioma were published in the Lung Cancer.
- 04 Jun 2024 Results(n=40) evaluating the effects of sMSLN on a MSLN-targeting antibody, anetumab, and explore methods to reduce sMSLN , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 23 Sep 2023 Planned End Date changed from 8 Jul 2024 to 21 Sep 2024.